{"brief_title": "Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure", "brief_summary": "The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).", "condition": "Prostatic Neoplasms", "intervention_type": "Drug", "intervention_name": "Atrasentan", "criteria": "Inclusion Criteria: - prostate adenocarcinoma, - radical prostatectomy, - PSA between 0.4 and 5 ng/mL, - PSADT < 1 year Exclusion Criteria: - previous hormonal therapy, - salvage therapy to the pelvis within 3 months prior to randomization", "gender": "Male", "minimum_age": "19 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00038662.xml"}